Form 4: Arcadia Biosciences Director Deborah Carosella Acquires Stock Options

Director Deborah Carosella acquired stock options in Arcadia Biosciences, Inc. on August 19, 2024.

Summary

• Deborah Carosella, a director of Arcadia Biosciences, Inc., filed a Form 4 indicating changes in beneficial ownership.
• On August 19, 2024, Carosella acquired 10,909 stock options with an exercise price of $2.71.
• These options vest 100% on the earlier of August 19, 2025, or the date of the Issuer's next Annual Meeting of Stockholders, contingent upon continued service.
• Following the transaction, Carosella directly owns 13,255 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating a director's acquisition of stock options, which can be seen as a positive sign of confidence, but it's not overwhelmingly positive or negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon continued service and will occur no later than August 19, 2025, or the date of the next Annual Meeting of Stockholders.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of stock options by a director may positively influence shareholder sentiment.

Key Dates

Keywords

Arcadia Biosciences, RKDA, Form 4, Stock Options, Beneficial Ownership, Director, Carosella, Equity Securities